TABLE 2.
Clinical chemistry profiles of the study participants1
| Variables (normal range) | Placebo (n = 12) | Soy isoflavone treatment (n = 12) | P2 |
| Serum chemistry profile | |||
| Sodium (135–145 mmol/L) | 142.2 ± 1.83 | 143.2 ± 1.5 | 0.15 |
| Potassium (3.3–5.0 mmol/L) | 4.1 ± 0.3 | 4.0 ± 0.5 | 0.65 |
| Chloride (95–110 mmol/L) | 105.1 ± 2.7 | 106.5 ± 1.3 | 0.12 |
| Calcium (8.6–10.5 mg/dL) | 9.6 ± 0.5 | 9.7 ± 0.5 | 0.57 |
| Carbon dioxide (24–32 mmol/L) | 27.9 ± 2.2 | 27.3 ± 2.2 | 0.53 |
| Glucose (70–110 mg/dL) | 98.0 ± 15.0 | 95.8 ± 13.5 | 0.71 |
| Uric acid (3.5–8.5 mg/dL) | 4.0 ± 0.9 | 4.3 ± 1.3 | 0.54 |
| BUN (8–22 mg/dL) | 14.1 ± 3.2 | 13.6 ± 2.8 | 0.69 |
| Creatinine (0.5–1.3 mg/dL) | 0.9 ± 0.2 | 0.9 ± 0.1 | 0.62 |
| Total bilirubin (0.3–1.3 mg/dL) | 0.6 ± 0.2 | 0.5 ± 0.2 | 0.29 |
| ALT (5–54 U/L) | 23.3 ± 7.7 | 21.4 ± 10.9 | 0.64 |
| AST (15–43 U/L) | 23.0 ± 6.4 | 19.8 ± 3.4 | 0.13 |
| Alkaline phosphatase (35–115 U/L) | 75.4 ± 17.4 | 81.8 ± 15.0 | 0.34 |
| Albumin (3.4–4.8 g/dL) | 4.8 ± 0.2 | 4.8 ± 0.2 | 0.78 |
| Total protein (6.3–8.3 g/dL) | 7.8 ± 0.5 | 7.7 ± 0.5 | 0.76 |
| Lipid profile (fasting) | |||
| Total cholesterol (0–200 mg/dL) | 218.9 ± 32.3 | 221.5 ± 36.3 | 0.86 |
| Triglyceride (35–160 mg/dL) | 114.2 ± 34.8 | 113.6 ± 50.1 | 0.97 |
| HDL cholesterol (>35 mg/dL) | 64.0 ± 18.5 | 64.3 ± 16.1 | 0.97 |
| LDL cholesterol (<130 mg/dL) | 132.1 ± 27.7 | 135.3 ± 28.1 | 0.79 |
| Endocrine profile | |||
| TSH (0.35–5.5 μIU/mL) | 2.0 ± 1.0 | 1.3 ± 0.7 | 0.07 |
| FT4 (0.80–1.80 ng/dL) | 1.1 ± 0.2 | 2.8 ± 3.1 | 0.06 |
| Hormone profile | |||
| FSH (23–117 mIU/mL)4 | 72.3 ± 29.1 | 61.9 ± 25.7 | 0.36 |
1
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; FSH, follicle-stimulating hormone; FT4, free thyroxine; TSH, thyroid-stimulating hormone.
2
Derived by using an independent-samples t test for the comparison between the placebo and treatment groups.
3
Mean ± SD (all such values).
4
Range of values for postmenopausal females.